Compare Stocks: BBNX, PLSE, IRTC, and ATRC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRC AtriCure	$57.79 -1.1%	$47.70	$25.36 ▼ $61.70	$2.94B	1.26	869,976 shs	145,409 shs
BBNX Beta Bionics	$19.69 -4.0%	$18.22	$8.80 ▼ $32.71	$887.25M	3.37	1.19 million shs	145,937 shs
IRTC iRhythm Technologies	$112.04 -0.5%	$118.34	$100.85 ▼ $212.00	$3.69B	1.31	603,544 shs	63,845 shs
PLSE Pulse Biosciences	$50.46 -3.6%	$45.87	$12.56 ▼ $58.90	$3.54B	1.63	386,425 shs	93,036 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRC AtriCure	+0.05%	+0.15%	+20.33%	+108.76%	+65.94%
BBNX Beta Bionics	-4.60%	-6.90%	+4.06%	+30.95%	+5.07%
IRTC iRhythm Technologies	+2.01%	+2.01%	-6.36%	-5.34%	-34.08%
PLSE Pulse Biosciences	+1.34%	-1.86%	+9.99%	+88.68%	+194.43%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRC AtriCure	$57.79 -1.1%	$47.70	$25.36 ▼ $61.70	$2.94B	1.26	869,976 shs	145,409 shs
BBNX Beta Bionics	$19.69 -4.0%	$18.22	$8.80 ▼ $32.71	$887.25M	3.37	1.19 million shs	145,937 shs
IRTC iRhythm Technologies	$112.04 -0.5%	$118.34	$100.85 ▼ $212.00	$3.69B	1.31	603,544 shs	63,845 shs
PLSE Pulse Biosciences	$50.46 -3.6%	$45.87	$12.56 ▼ $58.90	$3.54B	1.63	386,425 shs	93,036 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRC AtriCure	+0.05%	+0.15%	+20.33%	+108.76%	+65.94%
BBNX Beta Bionics	-4.60%	-6.90%	+4.06%	+30.95%	+5.07%
IRTC iRhythm Technologies	+2.01%	+2.01%	-6.36%	-5.34%	-34.08%
PLSE Pulse Biosciences	+1.34%	-1.86%	+9.99%	+88.68%	+194.43%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRC AtriCure	2.75	Moderate Buy	$53.30	-8.75% Downside
BBNX Beta Bionics	2.54	Moderate Buy	$22.91	11.64% Upside
IRTC iRhythm Technologies	2.94	Moderate Buy	$179.93	59.79% Upside
PLSE Pulse Biosciences	2.86	Moderate Buy	$50.20	-4.05% Downside

Current Analyst Ratings Breakdown

Latest BBNX, IRTC, PLSE, and ATRC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	BBNX Beta Bionics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$23.00 ➝ $28.00
9/23/2026	PLSE Pulse Biosciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$70.00
9/23/2026	BBNX Beta Bionics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$28.00
9/23/2026	BBNX Beta Bionics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$28.00
9/23/2026	PLSE Pulse Biosciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$70.00
9/17/2026	ATRC AtriCure	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$65.00
9/15/2026	BBNX Beta Bionics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$22.00 ➝ $23.00
9/15/2026	BBNX Beta Bionics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
9/15/2026	BBNX Beta Bionics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $20.00
9/15/2026	BBNX Beta Bionics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$14.00 ➝ $16.00
9/14/2026	IRTC iRhythm Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRC AtriCure	$534.53M	5.56	$0.31 per share	186.52	$9.89 per share	5.91
BBNX Beta Bionics	$100.25M	9.21	N/A	N/A	$6.53 per share	3.14
IRTC iRhythm Technologies	$747.14M	4.97	N/A	N/A	$4.74 per share	23.76
PLSE Pulse Biosciences	$350K	10,583.59	N/A	N/A	$1.19 per share	43.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRC AtriCure	-$11.45M	$0.21	278.16	129.80	N/A	1.85%	2.34%	1.77%	11/4/2026 (Estimated)
BBNX Beta Bionics	-$73.20M	-$1.65	N/A	N/A	N/A	-61.31%	-26.30%	-23.25%	N/A
IRTC iRhythm Technologies	-$44.55M	-$0.43	N/A	77.66	N/A	-1.69%	10.11%	1.53%	10/29/2026 (Estimated)
PLSE Pulse Biosciences	-$72.78M	-$1.18	N/A	N/A	N/A	-6,755.78%	-94.42%	-79.96%	11/4/2026 (Estimated)

Latest BBNX, IRTC, PLSE, and ATRC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	IRTC iRhythm Technologies	-$0.04	$0.58	+$0.62	-$0.01	$219.30 million	$224.17 million
8/6/2026	Q2 2026	PLSE Pulse Biosciences	-$0.2933	-$0.36	-$0.0667	-$0.36	$0.53 million	$0.43 million
7/29/2026	Q2 2026	BBNX Beta Bionics	-$0.62	-$0.53	+$0.09	-$0.53	N/A	$32.01 million
7/23/2026	Q2 2026	ATRC AtriCure	-$0.0017	$0.18	+$0.1817	$0.18	$151.80 million	$153.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRC AtriCure	N/A	N/A	N/A	N/A	N/A
BBNX Beta Bionics	N/A	N/A	N/A	N/A	N/A
IRTC iRhythm Technologies	N/A	N/A	N/A	N/A	N/A
PLSE Pulse Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRC AtriCure	0.14	4.22	3.19
BBNX Beta Bionics	N/A	8.88	7.96
IRTC iRhythm Technologies	3.50	3.86	3.74
PLSE Pulse Biosciences	N/A	9.63	9.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRC AtriCure	99.11%
BBNX Beta Bionics	N/A
IRTC iRhythm Technologies	N/A
PLSE Pulse Biosciences	76.95%

Insider Ownership

Company	Insider Ownership
ATRC AtriCure	4.00%
BBNX Beta Bionics	5.30%
IRTC iRhythm Technologies	0.98%
PLSE Pulse Biosciences	74.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRC AtriCure	1,350	50.87 million	48.83 million	Optionable
BBNX Beta Bionics	423	44.99 million	42.61 million	N/A
IRTC iRhythm Technologies	2,400	32.96 million	32.64 million	Optionable
PLSE Pulse Biosciences	116	70.80 million	18.41 million	Optionable

BBNX, PLSE, IRTC, and ATRC Headlines

Recent News About These Companies

Pulse Biosciences: Promising Technology, But Hard To Justify Its Valuation

September 27 at 6:25 PM | seekingalpha.com

Pulse Biosciences (NASDAQ:PLSE) Research Coverage Started at BTIG Research

September 26 at 2:12 AM | americanbankingnews.com

Pulse Biosciences stock reports 100 patient trial milestone

September 24, 2026 | ad-hoc-news.deA

Pulse Biosciences (NASDAQ:PLSE) Upgraded to Strong-Buy at BTIG Research

September 24, 2026 | marketbeat.com

Pulse Biosciences (NASDAQ:PLSE) Stock Price Up 3.3% - What's Next?

September 23, 2026 | marketbeat.com

1,446,611 Shares in Pulse Biosciences, Inc $PLSE Purchased by Bank of America Corp DE

September 22, 2026 | marketbeat.com

Pulse Biosciences Completes Enrollment in 100-Patient Thyroid Nodule Study

September 16, 2026 | finance.yahoo.com

Pulse Biosciences (NASDAQ:PLSE) Shares Gap Down - Should You Sell?

September 16, 2026 | marketbeat.com

Pulse Biosciences consensus price target increased 12.27% to $51.82

September 16, 2026 | msn.com

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

September 15, 2026 | finance.yahoo.com

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

September 15, 2026 | businesswire.com

Pulse Biosciences (NASDAQ:PLSE) Upgraded by Freedom Capmkts to Strong-Buy Rating

September 11, 2026 | marketbeat.com

Pulse Biosciences, Inc (NASDAQ:PLSE) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 11, 2026 | marketbeat.com

Pulse Biosciences (NASDAQ:PLSE) Reaches New 12-Month High - Should You Buy?

September 10, 2026 | marketbeat.com

Bank of New York Mellon Corp Invests $1.20 Million in Pulse Biosciences, Inc $PLSE

September 10, 2026 | marketbeat.com

Freedom Capital Markets initiates coverage of Pulse Biosciences with a buy rating

September 9, 2026 | msn.com

Why Pulse Biosciences Stock Popped Today

September 9, 2026 | fool.com

Pulse Biosciences (NASDAQ:PLSE) Trading Up 5.3% - Here's Why

September 9, 2026 | marketbeat.com

Pulse Biosciences (NASDAQ:PLSE) Shares Down 7.3% - Here's What Happened

September 8, 2026 | marketbeat.com

Pulse Biosciences (NASDAQ:PLSE) Upgraded to Hold at Wall Street Zen

September 6, 2026 | marketbeat.com

Insider Buying: Pulse Biosciences (NASDAQ:PLSE) COO Acquires $49,971.20 in Stock

September 3, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX, PLSE, IRTC, and ATRC Company Descriptions

AtriCure NASDAQ:ATRC

$57.79 -0.62 (-1.06%)

As of 11:40 AM Eastern

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Beta Bionics NASDAQ:BBNX

$19.69 -0.83 (-4.04%)

As of 11:40 AM Eastern

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

iRhythm Technologies NASDAQ:IRTC

$112.04 -0.57 (-0.50%)

As of 11:40 AM Eastern

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Pulse Biosciences NASDAQ:PLSE

$50.46 -1.86 (-3.56%)

As of 11:40 AM Eastern

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BBNX, IRTC, PLSE, and ATRC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BBNX, IRTC, PLSE, and ATRC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BBNX, PLSE, IRTC, and ATRC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX, PLSE, IRTC, and ATRC Company Descriptions

AtriCure NASDAQ:ATRC

Beta Bionics NASDAQ:BBNX

iRhythm Technologies NASDAQ:IRTC

Pulse Biosciences NASDAQ:PLSE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BBNX, IRTC, PLSE, and ATRC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BBNX, IRTC, PLSE, and ATRC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BBNX, PLSE, IRTC, and ATRC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX, PLSE, IRTC, and ATRC Company Descriptions

AtriCure NASDAQ:ATRC

Beta Bionics NASDAQ:BBNX

iRhythm Technologies NASDAQ:IRTC

Pulse Biosciences NASDAQ:PLSE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools